NCT05607329 is a NA clinical trial of Secondary cytoreduction in Relapsed Ovarian Cancer, sponsored by Women's Hospital School Of Medicine Zhejiang University.

Who is sponsoring NCT05607329?

NCT05607329 is sponsored by Women's Hospital School Of Medicine Zhejiang University.

What drugs are being tested in NCT05607329?

Interventions in NCT05607329: Secondary cytoreduction, Chemotherapy.

What condition does NCT05607329 study?

NCT05607329 studies Relapsed Ovarian Cancer.

Is NCT05607329 still recruiting?

NCT05607329 is currently recruiting now. Last updated 7 November 2022.

Last reviewed 2022-11-07 · How we verify

NCT05607329

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial

Recruiting now NA Last updated 7 November 2022

What this trial tests

NA trial testing Secondary cytoreduction in Relapsed Ovarian Cancer in 400 participants. Currently enrolling.

Timeline

1 May 2021

Primary endpoint
1 May 2026

1 May 2028

Quick facts

Lead sponsor	Women's Hospital School Of Medicine Zhejiang University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	400
Start date	1 May 2021
Primary completion	1 May 2026
Estimated completion	1 May 2028
Sites	1 location across China

Drugs / interventions tested

Secondary cytoreduction
Chemotherapy (chemotherapy) — full drug profile →

Conditions studied

Relapsed Ovarian Cancer — all drugs for Relapsed Ovarian Cancer →

Sponsor

Women's Hospital School Of Medicine Zhejiang University

Who can join

Adults 18 to 70, female only, with Relapsed Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to carry out a multi-center, randomized controlled study on patients with recurrent ovarian cancer after PARPi maintenance, to explore the clinicopathological and molecular characteristics of patients with recurrent ovarian cancer after PARPi maintenance, and to clarify whether patients with recurrent ovarian cancer after PARPi maintenance for more than 6 months are sensitive to platinum drugs, and the value of secondary tumor cell reduction in such treatment, In order to provide evidence-based medicine basis for the standardized treatment mode of recurrent ovarian cancer after PARPi maintenance treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Secondary cytoreduction surgery for recurrent epithelial ovarian cancer patients after PARPi maintenance: A multicenter, randomized, controlled clinical trial.
Chen T, Xu J, Xia B, Wang H, et al · · 2024 · cited 5× · PMID 38159938 · DOI 10.1136/ijgc-2023-004978
Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer.
Mukherjee UA, Miller RE, Ledermann JA. · · 2025 · cited 2× · PMID 40529205 · DOI 10.1177/17588359251343973

Verify or expand the search:

Other trials of Secondary cytoreduction

Trials testing the same drug.

NCT06544460 — Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients · Phase 2 · not yet recruiting

Other recruiting trials for Relapsed Ovarian Cancer

Currently open trials in the same condition.

NCT05080556 — Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade En · Phase 2 · recruiting
NCT01874353 — Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy · Phase 3 · active not recruiting

Other Women's Hospital School Of Medicine Zhejiang University trials

Trials by the same sponsor.

NCT07369986 — Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer · Phase 2 · not yet recruiting
NCT07244965 — Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervica · Phase 2 · not yet recruiting
NCT06561308 — Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer · Phase 2 · recruiting
NCT07106853 — Prenatal Cell-free DNA Screening in Pregnancies With Diverse Genetic Risk Profiles Utilizing Targeted and Whole-exome Se · not yet recruiting
NCT07082530 — A RCT of Labor Induction at 39 Weeks in Low - Risk Women in China · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05607329 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Women's Hospital School Of Medicine Zhejiang University
Last refreshed: 7 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05607329.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing